| Symposium review: Mechanisms linking metabolic stress with innate immunity in the endometrium IM Sheldon, JG Cronin, M Pospiech, ML Turner Journal of dairy science 101 (4), 3655-3664, 2018 | 52 | 2018 |
| sRNA-controlled iron sparing response in Staphylococci RH Coronel-Tellez, M Pospiech, M Barrault, W Liu, V Bordeau, C Vasnier, ... Nucleic acids research 50 (15), 8529-8546, 2022 | 15 | 2022 |
| Bisphosphonate inhibitors of squalene synthase protect cells against cholesterol‐dependent cytolysins M Pospiech, S Owens, DJ Miller, K Austin-Muttitt, J Mullins, J Cronin, ... The FASEB Journal 35 (6), 1, 2021 | 8 | 2021 |
| Deletion of CD36 exhibits limited impact on normal hematopoiesis and the leukemia microenvironment Y Meng, M Pospiech, A Ali, R Chandwani, M Vergel, S Onyemaechi, ... Cellular & Molecular Biology Letters 28 (1), 45, 2023 | 5 | 2023 |
| Prediction of peptide and TCR CDR3 loops in formation of class I MHC-peptide-TCR complexes using molecular models with solvation NM Mehta, Y Li, V Patel, W Li, N Morningstar-Kywi, M Pospiech, ... Computational Vaccine Design, 273-287, 2023 | 3 | 2023 |
| Profiling the epigenetic landscape of the antigen receptor repertoire: The missing epi-immunogenomics data R Aburajab, M Pospiech, H Alachkar Nature methods 20 (4), 477-481, 2023 | 3 | 2023 |
| Analysis of ASXL1 Mutated T Cells in Patients with Myeloid Malignancies E Fernandez, J Sanchez, G Liang, M Pospiech, H Li, Z Manojlovic, ... Blood 142, 6453, 2023 | 1 | 2023 |
| Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia M Pospiech, M Tamizharasan, YC Wei, AMS Kumar, M Lou, J Milstein, ... Frontiers in Immunology 14, 1236514, 2023 | 1 | 2023 |
| Loss of Cd36 expression has limited impact on mouse normal hematopoiesis O Meng, M Pospiech, R Chandwani, A Ali, G Yaghmour, H Alachkar Blood 140 (Supplement 1), 11395-11396, 2022 | 1 | 2022 |
| The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia M Pospiech, J Beckford, AMS Kumar, M Tamizharasan, J Brito, G Liang, ... International Immunopharmacology 138, 112376, 2024 | | 2024 |
| FLT3/CD99 Bispecific antibody-based nanoparticles (BiAbs) for Acute Myeloid Leukemia A Ali, A Phan, V Vaikari, M Park, M Pospiech, R Chu, Y Meng, JA MacKay, ... Cancer Research Communications, 2024 | | 2024 |
| Establishment and characterization of a novel inducible Apoc2 knockout mouse model to study the roles of Apoc2 in normal hematopoiesis X Zhang, R Chandwani, M Pospiech, Y Meng, K Dhuri, B Thakker, A Ali, ... Cancer Research 84 (6_Supplement), 5336-5336, 2024 | | 2024 |
| Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99-A192 ScFv-ELP nanoparticle treatment S Kadam, A Ali, M Pospiech, S Onyemaechi, Y Meng, K Dhuri, A Mackay, ... Cancer Research 84 (6_Supplement), 2363-2363, 2024 | | 2024 |
| The DNA methylation landscape across the TCR loci genes in patients with acute myeloid leukemia M Pospiech, J Beckford, AM Kumar, M Tamizharasan, J Brito, G Liang, ... Cancer Research 84 (6_Supplement), 7011-7011, 2024 | | 2024 |
| Functional characterization of the impact of CD36 deletion on normal hematopoiesis and the leukemia microenvironment Y Meng, M Pospiech, A Ali, R Chandwani, S Onyemaechi, G Yaghmour, ... Cancer Research 83 (7_Supplement), 1732-1732, 2023 | | 2023 |
| LOSS OF CD36 EXPRESSION HAS LIMITED IMPACT ON NORMAL HEMATOPOIESIS Y Meng, M Pospiech, H Alachkar EXPERIMENTAL HEMATOLOGY 111, S112-S112, 2022 | | 2022 |
| 3136–LOSS OF CD36 EXPRESSION HAS LIMITED IMPACT ON NORMAL HEMATOPOIESIS Y Meng, M Pospiech, H Alachkar Experimental Hematology 111, S113, 2022 | | 2022 |
